Merus (NASDAQ:MRUS) was downgraded by investment analysts at ValuEngine from a “hold” rating to a “sell” rating in a note issued to investors on Monday, ValuEngine reports.
Several other analysts have also recently commented on MRUS. Zacks Investment Research raised Merus from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a research report on Wednesday, October 2nd. Roth Capital began coverage on Merus in a research report on Friday, June 28th. They issued a “buy” rating and a $20.00 target price for the company. Finally, BidaskClub raised Merus from a “hold” rating to a “buy” rating in a research report on Thursday, September 26th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $23.43.
Shares of Merus stock traded up $0.22 during midday trading on Monday, hitting $16.63. The company’s stock had a trading volume of 49,481 shares, compared to its average volume of 36,087. The firm has a market capitalization of $376.29 million, a P/E ratio of -9.04 and a beta of 0.24. The stock has a 50-day simple moving average of $17.23 and a 200-day simple moving average of $15.44. Merus has a 1-year low of $11.00 and a 1-year high of $20.95.
Merus (NASDAQ:MRUS) last issued its earnings results on Monday, August 19th. The biotechnology company reported ($0.57) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.54) by ($0.03). The business had revenue of $6.27 million during the quarter, compared to analyst estimates of $8.62 million. Merus had a negative return on equity of 41.68% and a negative net margin of 104.10%. On average, analysts forecast that Merus will post -1.73 EPS for the current year.
Large investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. raised its holdings in shares of Merus by 63.5% during the second quarter. JPMorgan Chase & Co. now owns 8,722 shares of the biotechnology company’s stock worth $123,000 after acquiring an additional 3,389 shares in the last quarter. Athanor Capital LP purchased a new stake in shares of Merus during the second quarter worth $334,000. Morgan Stanley raised its holdings in shares of Merus by 3.1% during the second quarter. Morgan Stanley now owns 92,776 shares of the biotechnology company’s stock worth $1,359,000 after acquiring an additional 2,788 shares in the last quarter. Finally, Artal Group S.A. raised its holdings in shares of Merus by 16.7% during the second quarter. Artal Group S.A. now owns 350,000 shares of the biotechnology company’s stock worth $5,128,000 after acquiring an additional 50,000 shares in the last quarter. Institutional investors and hedge funds own 52.00% of the company’s stock.
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.
Further Reading: How does a security become overbought?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.